Evaluation of Intra-arterial Thrombolysis in Treatment of Cosmetic Facial Filler-related Ophthalmic Artery Occlusion.
With an increase in recent years in the number of people receiving cosmetic facial injection treatments of hyaluronic acid (HA), the incidence of HA embolism has also commensurately increased. HA embolism leads to serious complications including blindness, eye and eyelid movement disorders, skin necrosis and cerebral embolism. However, there is a lack of robust clinical evidence regarding the benefits of treatment for HA embolism by Intra-arterial thrombolysis (IAT) therapy. In this study, we included 24 patients with a decrease in visual acuity and other complications induced by facial HA injection. These patients underwent emergency IAT therapy by injection of hyaluronidase (500-1,500 units) alone or hyaluronidase (750-1,500 units) combined with urokinase (100,000-250,000 units), followed in both cases by a general symptomatic treatment and nutritional therapy. In the 24 patients, 10 patients (42%) ultimately had improvements to visual acuity, even in cases when the clinical application of the thrombolytic treatments had passed the recommended window for optimal treatment. In all cases the patients' facial skin necrosis was restored to nearly normal appearance. In addition, we found that hyaluronidase combined with urokinase was a more effective therapy than hyaluronidase alone. Our results indicate that IAT therapy is beneficial to patients suffering from blindness induced by HA embolism. IAT therapy was shown to be worthy of clinical application because it alleviated the impairment to patients' vision , and was also beneficial in the recovery from other serious complications including eye movement disorder, eye edema, headaches, and skin necrosis.